Cancer, Cognitive Impairment, Insomnia
Conditions
Keywords
Cognitive Behaviour Therapy for Insomnia, CBT-I, Cancer, Insomnia, Sleep, Perceived Cognitive Impairment
Brief summary
The investigators will answer the question of whether treating insomnia using Cognitive Behavior Therapy for Insomnia (CBT-I) can improve perceived cognitive impairment (PCI) in cancer survivors compared to a waitlist control group. The investigators will recruit 124 people with insomnia and cognitive complaints who have completed cancer treatment at least 6 months prior to the study.
Detailed description
The investigators will conduct a randomized controlled trial of immediate treatment with CBT-I compared to a delayed treatment group with 124 cancer survivors who have completed primary treatment at least 6 months prior and report PCI and insomnia. Participants who are randomized to the immediate treatment group will receive CBT-I over the course of seven weekly one hour sessions, after which the delayed treatment group will receive the intervention. Both groups will complete follow up assessments three and six months after completing treatment. PCI will be assessed using the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) as the primary outcome. To provide an objective assessment of cognition, the investigators have included the neurocognitive measures recommended by the International Cognition and Cancer Task Force. Other measures will include fatigue, anxiety, depression, and work productivity. The investigators hypothesize that the online CBT-I group will report significantly greater improvements in perceived cognitive function compared to the waitlist control immediately post-treatment (primary endpoint). The investigators also hypothesize that these improvements will be maintained up at 6-months follow up (secondary endpoint).
Interventions
CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Sponsors
Study design
Eligibility
Inclusion criteria
for individuals with non-hematological malignancies: * Men and women who are easily able to understand and read English * No current evidence of cancer or clinically stable/inactive disease * Received and completed all adjuvant treatments at least 6 months prior to study entry to allow for neural stabilization and recovery * Self-reported PCI as indicated by a score of sometimes or higher (quite a lot or always) on at least two out of three questions that assess memory, concentration, and attention * Meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for insomnia disorder and have a score of 8 or greater on the Insomnia Severity Index (ISI) * Have good performance status as indicated by an Eastern Cooperative Oncology Group (ECOG) score of 0-2 * Have high-speed internet connection, webcam, and are fluent using the internet Inclusion Criteria for individuals with hematological malignancies: * Men and women who are easily able to understand and read English * A diagnosis of a hematological malignancy currently in remission * Completed cancer treatments including transplant, chemotherapy and/or immunotherapy at least 6 months prior to study entry * Self-reported PCI as indicated by a score of sometimes or higher (quite a lot or always) on at least two out of three questions that assess memory, concentration, and attention * Meet the DSM-5 criteria for insomnia disorder and have a score of 8 or greater on the Insomnia Severity Index * Have good performance status as indicated by an ECOG score of 0-2 * Have high-speed internet connection, webcam, and are fluent using the internet
Exclusion criteria
for individuals with and without hematological malignancies: * Another sleep disorder, besides insomnia, that is not adequately treated (ie: untreated obstructive sleep apnea) * The presence of another psychological disorder that is not currently stable and/or would impair the ability to participate in the study * A major sensory deficit (e.g. blindness) * A neurologic or major medical condition known to affect cognitive function (e.g., Parkinson's) * A history of cranial radiation * A history of any other condition that may affect cognitive functioning (e.g., traumatic brain injury) * Previous experience with CBT-I Other considerations: * Participants will not be excluded for using psychotropic medication prior to study entry (e.g. antidepressants) provided that the dose was not recently altered (stable over the previous 6 weeks) * Considering the potential for prescription of medications to help with sleep (e.g. hypnotics, sedatives, and antidepressants) within the cancer population, medication use throughout the study will be tracked and adjusted for in the statistical analysis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3 | Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up | The FACT-Cog was used to measure perceived cognitive impairment (PCI). It is a 37-item questionnaire with four cognitive subscales: perceived cognitive impairments, impact on quality of life, comments from others, and perceived cognitive abilities. Responses range from 0, ''never,'' to 4, ''several times a day,'' in the previous 7 days and negatively worded items are reverse scored to create subscale scores. Scores on the PCI subscale can range from 0 to 72 points, with a higher score indicative of better self-reported cognitive functioning and quality of life. A change of 5.9-points has been established as clinically meaningful change on the FACT-Cog PCI subscale |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sleep Efficiency Measured by The Consensus Sleep Diary (CSD) | Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up | Sleep efficiency is the percentage of time spent asleep while in bed. It is calculated by dividing the amount of time spent asleep (in minutes) by the total amount of time in bed (in minutes). The unit of measure is a percentage and is averaged over the whole week for the total sleep efficiency score. |
| Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD) | Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up | The sleep diary will be used to calculate sleep-onset latency, which is the length of time that it takes to accomplish the transition from full wakefulness to sleep. The unit of measure is minutes and is averaged over the whole week for the total sleep onset latency score. |
| Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD) | Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up | The sleep diary will be used to calculate wake after sleep onset, which refers to periods of wakefulness occurring after defined sleep onset. The score is reported in minutes and is averaged over the whole week for the total wake after sleep onset. |
| Total Sleep Time Measured by The Consensus Sleep Diary (CSD): | Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up | The sleep diary will be used to calculate total sleep time. The score is reported in minutes and is averaged over the whole week for the total sleep time. |
| Hospital Anxiety and Depression Scale (HADS) | Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up | Anxiety and Depression will be measured using the HADS, which is a 14-item, self-rated instrument for anxiety (7 items) and depression (7 items) symptoms in the past week and has been extensively used in people with cancer. Scores range from 0-21 with below 7 indicating a non-case and the higher the score indicates greater symptom severity. |
| Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) | Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up | Fatigue will be measured using the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), which is a 30 item self-report measure comprised of five subscales (general, emotional, physical, mental, vigor) and a total fatigue score. Each subscale score ranges from 0 to 24. The Total MSFI-SF score is calculated by adding the general, physical, emotional and mental subscale scores and subtracting vigor subscale score. Total MFSI-SF score ranges from -24 to 96 with a higher score indicating higher levels of cancer-related fatigue experienced by the patient. |
| The Insomnia Severity Index (ISI) | Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up | The ISI is designed to specifically assess the severity of insomnia symptoms, the impact on daytime functioning, and the amount of associated distress. The ISI has 7 questions, which are summed to compute a total score. The range of the ISI is 0-28 with the higher the value, the more severe the insomnia severity. |
| The Controlled Oral Word Association Test (COWAT) | Change from Baseline to Week 8, 3 month follow up, 6 month follow up | The COWAT is a measure of verbal fluency, cognitive and motor speed, cognitive flexibility, strategy utilization, suppression of interference, and response inhibition. The total score is the total number of different words produced for all three letters in a timeframe of 3 minutes (1 minute for each letter). The scores are adjusted based on age and education level. A greater score indicates better verbal fluency. A score less then 33 indicates below average performance, scores between 34 and 45 indicate average performance, and scores greater than 45 are above average, with scores greater than 52 indicate superior performance. A minimum score is 0 (no words produced) and there is no set maximum score, as it depends on how many words can be produced in the given time frame. |
| The Digit Span | Change from Baseline to Week 8, 3 month follow up, 6 month follow up | The Digit Span test is a subtest of both the Wechsler Adult Intelligence Scale (WAIS) and the Wechsler Memory Scale (WMS). Part A of digit span (the forward span) captures attention efficiency and capacity, and part B (the backward span) is an executive task dependent on working memory. The Digit Span subtest will be scored as one summary value. The unit of measure is the total recall. Scores on this measure range from 0-48, where greater scores indicates greater attention efficiency, capacity and working memory. |
| The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) | Change from Baseline to Week 8, 3 month follow up, 6 month follow up | The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) is composed of 75 items within nine non-overlapping theoretically and empirically derived clinical scales. It has 2 broad indexes (Behavioural Regulation and Metacognition), an overall summary score, and three validity scales. This analysis examines the overall summary score. T scores (M = 50, SD = 10; transformations of the raw scale scores) are used to interpret the individual's level of executive functioning. Traditionally, T scores at or above 65 are considered clinically significant. Greater scores indicate greater deficits in executive functioning. |
| The Work Productivity and Activity Impairment (WPAI) | Change from Baseline to Week 8, 3 month follow up, 6 month follow up | The WPAI questionnaire was developed for the purpose of collecting productivity loss data within clinical trials and is suitable for direct translation into a monetary figure. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. |
| Credibility/Expectancy Questionnaire (CEQ) | Baseline | The Credibility/Expectancy Questionnaire (CEQ) is a 6-item questionnaire that captures both credibility beliefs and outcome expectancy. Questions on this scale are rated on a 1-to-9 point or 0-100% Likert scale, depending on the exact question. The scale was adapted to separately assess: (1) credibility beliefs for insomnia; (2) credibility beliefs for PCI; (3) expectancy beliefs for insomnia; and (4) expectancy beliefs for PCI. Since the CEQ utilizes two scales during the administration (1-9, and 0-100%), a composite score was derived for each factor (expectancy and credibility) by first standardizing the individual items and then summing those items for each factor yielding total scores, where higher values indicate stronger credibility and expectancy beliefs. Credibility beliefs scores ranged from 0 to 23 and expectancy beliefs scores ranged from 0 to 27. |
| The Hopkins Verbal Learning Test-Revised (HVLT-R) | Change from Baseline to Week 8, 3 month follow up, 6 month follow up | The Hopkins Verbal Learning Test-Revised (HVLT-R) is a brief assessment of verbal learning and memory (immediate recall, delayed recall, delayed recognition). When scoring the HVLT-R, the three learning trials are combined to calculate a total recall score; the delayed recall trial creates the delayed recall score; the retention (%) score is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. These scores are then converted to an age-based T score (Mean=50, SD=10). Higher scores represent better verbal learning and memory. |
Countries
Canada
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene. | 63 |
| Waitlist Control Group Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene. | 69 |
| Total | 132 |
Baseline characteristics
| Characteristic | Waitlist Control Group | Total | Cognitive Behaviour Therapy for Insomnia (CBT-I) |
|---|---|---|---|
| Age, Continuous | 61.25 years STANDARD_DEVIATION 10.6 | 60.28 years STANDARD_DEVIATION 11.26 | 59.21 years STANDARD_DEVIATION 11.93 |
| Baseline insomnia score | 17.88 units on a scale STANDARD_DEVIATION 3.83 | 17.59 units on a scale STANDARD_DEVIATION 3.69 | 17.27 units on a scale STANDARD_DEVIATION 3.53 |
| Baseline perceived cognitive impairment score | 38.80 units on a scale STANDARD_DEVIATION 13.86 | 39.1 units on a scale STANDARD_DEVIATION 13.1 | 39.40 units on a scale STANDARD_DEVIATION 12.32 |
| Cancer stage Stage 0/in situ | 3 Participants | 4 Participants | 1 Participants |
| Cancer stage Stage I | 15 Participants | 27 Participants | 12 Participants |
| Cancer stage Stage II | 10 Participants | 23 Participants | 13 Participants |
| Cancer stage Stage III | 13 Participants | 28 Participants | 15 Participants |
| Cancer stage Stage IV | 5 Participants | 7 Participants | 2 Participants |
| Cancer stage Unknown/not applicable | 23 Participants | 43 Participants | 20 Participants |
| Cancer treatments received Chemotherapy | 35 Participants | 81 Participants | 46 Participants |
| Cancer treatments received Hormone therapy | 29 Participants | 42 Participants | 13 Participants |
| Cancer treatments received Other | 4 Participants | 8 Participants | 4 Participants |
| Cancer treatments received Radiation | 38 Participants | 76 Participants | 38 Participants |
| Cancer treatments received Surgery | 65 Participants | 117 Participants | 52 Participants |
| Cancer type Breast | 29 Participants | 54 Participants | 25 Participants |
| Cancer type Female genitourinary | 5 Participants | 11 Participants | 6 Participants |
| Cancer type GI tract | 5 Participants | 7 Participants | 2 Participants |
| Cancer type Hematologic | 5 Participants | 16 Participants | 11 Participants |
| Cancer type Multiple types | 12 Participants | 23 Participants | 11 Participants |
| Cancer type Other | 2 Participants | 6 Participants | 4 Participants |
| Cancer type Prostate and male genitourinary | 5 Participants | 7 Participants | 2 Participants |
| Cancer type Skin | 6 Participants | 8 Participants | 2 Participants |
| Employment status Not working/retired | 48 Participants | 84 Participants | 36 Participants |
| Employment status Working (part or full-time) | 21 Participants | 48 Participants | 27 Participants |
| Race/Ethnicity, Customized BIPOC | 4 Participants | 10 Participants | 6 Participants |
| Race/Ethnicity, Customized White | 65 Participants | 122 Participants | 57 Participants |
| Region of Enrollment Canada | 69 participants | 132 participants | 63 participants |
| Sex: Female, Male Female | 52 Participants | 102 Participants | 50 Participants |
| Sex: Female, Male Male | 17 Participants | 30 Participants | 13 Participants |
| Time since cancer diagnosis (years) ≥10 | 26 Participants | 54 Participants | 28 Participants |
| Time since cancer diagnosis (years) <2 | 7 Participants | 14 Participants | 7 Participants |
| Time since cancer diagnosis (years) 2-4 | 21 Participants | 32 Participants | 11 Participants |
| Time since cancer diagnosis (years) 5-9 | 14 Participants | 31 Participants | 17 Participants |
| Time since insomnia began (months) | 88.56 months STANDARD_DEVIATION 79.23 | 93.63 months STANDARD_DEVIATION 75.39 | 99.19 months STANDARD_DEVIATION 71.17 |
| Years of education College (12-14 years) | 24 Participants | 42 Participants | 18 Participants |
| Years of education High school (≤11 years) | 2 Participants | 6 Participants | 4 Participants |
| Years of education Postsecondary (≥15 years) | 43 Participants | 84 Participants | 41 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 63 | 0 / 69 |
| other Total, other adverse events | 12 / 63 | 14 / 69 |
| serious Total, serious adverse events | 2 / 63 | 2 / 69 |
Outcome results
The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3
The FACT-Cog was used to measure perceived cognitive impairment (PCI). It is a 37-item questionnaire with four cognitive subscales: perceived cognitive impairments, impact on quality of life, comments from others, and perceived cognitive abilities. Responses range from 0, ''never,'' to 4, ''several times a day,'' in the previous 7 days and negatively worded items are reverse scored to create subscale scores. Scores on the PCI subscale can range from 0 to 72 points, with a higher score indicative of better self-reported cognitive functioning and quality of life. A change of 5.9-points has been established as clinically meaningful change on the FACT-Cog PCI subscale
Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3 | Baseline | 39.39 score on a scale | Standard Deviation 12.32 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3 | 8 weeks | 53.44 score on a scale | Standard Deviation 12.01 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3 | 4 weeks | 48.28 score on a scale | Standard Deviation 11.89 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3 | 6 months follow-up | 52.47 score on a scale | Standard Deviation 12.89 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3 | 3 months follow-up | 53.16 score on a scale | Standard Deviation 11.37 |
| Waitlist Control Group | The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3 | 6 months follow-up | 51.46 score on a scale | Standard Deviation 14.1 |
| Waitlist Control Group | The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3 | 3 months follow-up | 46.21 score on a scale | Standard Deviation 19.64 |
| Waitlist Control Group | The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3 | Baseline | 38.79 score on a scale | Standard Deviation 13.85 |
| Waitlist Control Group | The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3 | 4 weeks | 44.71 score on a scale | Standard Deviation 13.84 |
| Waitlist Control Group | The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3 | 8 weeks | 43.00 score on a scale | Standard Deviation 12.89 |
Credibility/Expectancy Questionnaire (CEQ)
The Credibility/Expectancy Questionnaire (CEQ) is a 6-item questionnaire that captures both credibility beliefs and outcome expectancy. Questions on this scale are rated on a 1-to-9 point or 0-100% Likert scale, depending on the exact question. The scale was adapted to separately assess: (1) credibility beliefs for insomnia; (2) credibility beliefs for PCI; (3) expectancy beliefs for insomnia; and (4) expectancy beliefs for PCI. Since the CEQ utilizes two scales during the administration (1-9, and 0-100%), a composite score was derived for each factor (expectancy and credibility) by first standardizing the individual items and then summing those items for each factor yielding total scores, where higher values indicate stronger credibility and expectancy beliefs. Credibility beliefs scores ranged from 0 to 23 and expectancy beliefs scores ranged from 0 to 27.
Time frame: Baseline
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Credibility/Expectancy Questionnaire (CEQ) | Baseline expectancy | 19.68 scores on a scale | Standard Deviation 4.48 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Credibility/Expectancy Questionnaire (CEQ) | Baseline credibility | 15.37 scores on a scale | Standard Deviation 4.42 |
| Waitlist Control Group | Credibility/Expectancy Questionnaire (CEQ) | Baseline credibility | 16.43 scores on a scale | Standard Deviation 3.94 |
| Waitlist Control Group | Credibility/Expectancy Questionnaire (CEQ) | Baseline expectancy | 20.28 scores on a scale | Standard Deviation 4.19 |
Hospital Anxiety and Depression Scale (HADS)
Anxiety and Depression will be measured using the HADS, which is a 14-item, self-rated instrument for anxiety (7 items) and depression (7 items) symptoms in the past week and has been extensively used in people with cancer. Scores range from 0-21 with below 7 indicating a non-case and the higher the score indicates greater symptom severity.
Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Hospital Anxiety and Depression Scale (HADS) | 3 month follow-up depression | 3.57 score on a scale | Standard Deviation 2.88 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Hospital Anxiety and Depression Scale (HADS) | 4 weeks depression | 4.45 score on a scale | Standard Deviation 3.48 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Hospital Anxiety and Depression Scale (HADS) | 6 month follow-up depression | 4.24 score on a scale | Standard Deviation 3.52 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Hospital Anxiety and Depression Scale (HADS) | 8 weeks depression | 3.14 score on a scale | Standard Deviation 3.29 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Hospital Anxiety and Depression Scale (HADS) | Baseline anxiety | 9.33 score on a scale | Standard Deviation 3.48 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Hospital Anxiety and Depression Scale (HADS) | 8 weeks anxiety | 5.89 score on a scale | Standard Deviation 3.31 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Hospital Anxiety and Depression Scale (HADS) | 4 weeks anxiety | 6.88 score on a scale | Standard Deviation 3.25 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Hospital Anxiety and Depression Scale (HADS) | 3 month follow-up anxiety | 6.04 score on a scale | Standard Deviation 3.79 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Hospital Anxiety and Depression Scale (HADS) | 6 month follow-up anxiety | 6.18 score on a scale | Standard Deviation 4.33 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Hospital Anxiety and Depression Scale (HADS) | Baseline depression | 7.90 score on a scale | Standard Deviation 2.88 |
| Waitlist Control Group | Hospital Anxiety and Depression Scale (HADS) | 6 month follow-up anxiety | 5.67 score on a scale | Standard Deviation 3.82 |
| Waitlist Control Group | Hospital Anxiety and Depression Scale (HADS) | Baseline depression | 6.39 score on a scale | Standard Deviation 3.72 |
| Waitlist Control Group | Hospital Anxiety and Depression Scale (HADS) | 4 weeks depression | 4.63 score on a scale | Standard Deviation 3.65 |
| Waitlist Control Group | Hospital Anxiety and Depression Scale (HADS) | 3 month follow-up depression | 5.90 score on a scale | Standard Deviation 2.36 |
| Waitlist Control Group | Hospital Anxiety and Depression Scale (HADS) | Baseline anxiety | 8.70 score on a scale | Standard Deviation 4.24 |
| Waitlist Control Group | Hospital Anxiety and Depression Scale (HADS) | 4 weeks anxiety | 7.97 score on a scale | Standard Deviation 3.78 |
| Waitlist Control Group | Hospital Anxiety and Depression Scale (HADS) | 3 month follow-up anxiety | 5.97 score on a scale | Standard Deviation 4.41 |
| Waitlist Control Group | Hospital Anxiety and Depression Scale (HADS) | 8 weeks depression | 3.09 score on a scale | Standard Deviation 3.14 |
| Waitlist Control Group | Hospital Anxiety and Depression Scale (HADS) | 6 month follow-up depression | 3.30 score on a scale | Standard Deviation 2.99 |
| Waitlist Control Group | Hospital Anxiety and Depression Scale (HADS) | 8 weeks anxiety | 7.08 score on a scale | Standard Deviation 4.47 |
Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)
Fatigue will be measured using the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), which is a 30 item self-report measure comprised of five subscales (general, emotional, physical, mental, vigor) and a total fatigue score. Each subscale score ranges from 0 to 24. The Total MSFI-SF score is calculated by adding the general, physical, emotional and mental subscale scores and subtracting vigor subscale score. Total MFSI-SF score ranges from -24 to 96 with a higher score indicating higher levels of cancer-related fatigue experienced by the patient.
Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) | 8 weeks | 4.72 score on a scale | Standard Deviation 16.17 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) | Baseline | 29.57 score on a scale | Standard Deviation 16.75 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) | 3 month follow-up | 9.13 score on a scale | Standard Deviation 16.44 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) | 6 month follow-up | 10.04 score on a scale | Standard Deviation 18.13 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) | 4 weeks | 16.52 score on a scale | Standard Deviation 17.5 |
| Waitlist Control Group | Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) | 6 month follow-up | 5.95 score on a scale | Standard Deviation 17.65 |
| Waitlist Control Group | Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) | 3 month follow-up | 6.79 score on a scale | Standard Deviation 18.41 |
| Waitlist Control Group | Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) | Baseline | 26.64 score on a scale | Standard Deviation 19.38 |
| Waitlist Control Group | Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) | 8 weeks | 6.05 score on a scale | Standard Deviation 19.62 |
| Waitlist Control Group | Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) | 4 weeks | 17.17 score on a scale | Standard Deviation 20.49 |
Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)
Sleep efficiency is the percentage of time spent asleep while in bed. It is calculated by dividing the amount of time spent asleep (in minutes) by the total amount of time in bed (in minutes). The unit of measure is a percentage and is averaged over the whole week for the total sleep efficiency score.
Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Sleep Efficiency Measured by The Consensus Sleep Diary (CSD) | 3 month follow-up | 88.58 percentage of sleep efficiency | Standard Deviation 8.02 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Sleep Efficiency Measured by The Consensus Sleep Diary (CSD) | 4 weeks | 87.18 percentage of sleep efficiency | Standard Deviation 8.17 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Sleep Efficiency Measured by The Consensus Sleep Diary (CSD) | Baseline | 73.22 percentage of sleep efficiency | Standard Deviation 12.45 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Sleep Efficiency Measured by The Consensus Sleep Diary (CSD) | 6 month follow-up | 88.52 percentage of sleep efficiency | Standard Deviation 7.88 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Sleep Efficiency Measured by The Consensus Sleep Diary (CSD) | 8 weeks | 89.63 percentage of sleep efficiency | Standard Deviation 7.1 |
| Waitlist Control Group | Sleep Efficiency Measured by The Consensus Sleep Diary (CSD) | 6 month follow-up | 87.83 percentage of sleep efficiency | Standard Deviation 6.81 |
| Waitlist Control Group | Sleep Efficiency Measured by The Consensus Sleep Diary (CSD) | 8 weeks | 89.33 percentage of sleep efficiency | Standard Deviation 6.41 |
| Waitlist Control Group | Sleep Efficiency Measured by The Consensus Sleep Diary (CSD) | 3 month follow-up | 87.22 percentage of sleep efficiency | Standard Deviation 7.62 |
| Waitlist Control Group | Sleep Efficiency Measured by The Consensus Sleep Diary (CSD) | Baseline | 74.03 percentage of sleep efficiency | Standard Deviation 13.58 |
| Waitlist Control Group | Sleep Efficiency Measured by The Consensus Sleep Diary (CSD) | 4 weeks | 88.10 percentage of sleep efficiency | Standard Deviation 6.24 |
Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)
The sleep diary will be used to calculate sleep-onset latency, which is the length of time that it takes to accomplish the transition from full wakefulness to sleep. The unit of measure is minutes and is averaged over the whole week for the total sleep onset latency score.
Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD) | Baseline | 40.56 minutes | Standard Deviation 32.4 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD) | 3 month follow-up | 16.70 minutes | Standard Deviation 18.44 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD) | 8 weeks | 12.68 minutes | Standard Deviation 8.98 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD) | 6 month follow-up | 14.71 minutes | Standard Deviation 10.41 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD) | 4 weeks | 16.68 minutes | Standard Deviation 15.73 |
| Waitlist Control Group | Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD) | 6 month follow-up | 22.26 minutes | Standard Deviation 20.24 |
| Waitlist Control Group | Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD) | 4 weeks | 16.98 minutes | Standard Deviation 13.43 |
| Waitlist Control Group | Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD) | Baseline | 41.48 minutes | Standard Deviation 34.22 |
| Waitlist Control Group | Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD) | 8 weeks | 15.41 minutes | Standard Deviation 11.7 |
| Waitlist Control Group | Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD) | 3 month follow-up | 21.43 minutes | Standard Deviation 16.04 |
The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)
The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) is composed of 75 items within nine non-overlapping theoretically and empirically derived clinical scales. It has 2 broad indexes (Behavioural Regulation and Metacognition), an overall summary score, and three validity scales. This analysis examines the overall summary score. T scores (M = 50, SD = 10; transformations of the raw scale scores) are used to interpret the individual's level of executive functioning. Traditionally, T scores at or above 65 are considered clinically significant. Greater scores indicate greater deficits in executive functioning.
Time frame: Change from Baseline to Week 8, 3 month follow up, 6 month follow up
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) | 8 weeks | 51.14 t score | Standard Deviation 10.72 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) | Baseline | 60.37 t score | Standard Deviation 10.31 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) | 3 month follow-up | 50.13 t score | Standard Deviation 10.67 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) | 6 month follow-up | 50.65 t score | Standard Deviation 10.39 |
| Waitlist Control Group | The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) | 6 month follow-up | 52.54 t score | Standard Deviation 13.6 |
| Waitlist Control Group | The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) | 8 weeks | 52.41 t score | Standard Deviation 11.3 |
| Waitlist Control Group | The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) | 3 month follow-up | 51.54 t score | Standard Deviation 11.08 |
| Waitlist Control Group | The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) | Baseline | 59.13 t score | Standard Deviation 11.28 |
The Controlled Oral Word Association Test (COWAT)
The COWAT is a measure of verbal fluency, cognitive and motor speed, cognitive flexibility, strategy utilization, suppression of interference, and response inhibition. The total score is the total number of different words produced for all three letters in a timeframe of 3 minutes (1 minute for each letter). The scores are adjusted based on age and education level. A greater score indicates better verbal fluency. A score less then 33 indicates below average performance, scores between 34 and 45 indicate average performance, and scores greater than 45 are above average, with scores greater than 52 indicate superior performance. A minimum score is 0 (no words produced) and there is no set maximum score, as it depends on how many words can be produced in the given time frame.
Time frame: Change from Baseline to Week 8, 3 month follow up, 6 month follow up
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Controlled Oral Word Association Test (COWAT) | 3 month follow-up | 51.04 adj score on a scale | Standard Deviation 12.91 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Controlled Oral Word Association Test (COWAT) | 8 weeks | 46.77 adj score on a scale | Standard Deviation 11.12 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Controlled Oral Word Association Test (COWAT) | 6 month follow-up | 50.02 adj score on a scale | Standard Deviation 11.44 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Controlled Oral Word Association Test (COWAT) | Baseline | 47.14 adj score on a scale | Standard Deviation 11.48 |
| Waitlist Control Group | The Controlled Oral Word Association Test (COWAT) | 6 month follow-up | 49.62 adj score on a scale | Standard Deviation 13.87 |
| Waitlist Control Group | The Controlled Oral Word Association Test (COWAT) | 8 weeks | 47.50 adj score on a scale | Standard Deviation 13.61 |
| Waitlist Control Group | The Controlled Oral Word Association Test (COWAT) | 3 month follow-up | 48.42 adj score on a scale | Standard Deviation 12.2 |
| Waitlist Control Group | The Controlled Oral Word Association Test (COWAT) | Baseline | 44.41 adj score on a scale | Standard Deviation 12.31 |
The Digit Span
The Digit Span test is a subtest of both the Wechsler Adult Intelligence Scale (WAIS) and the Wechsler Memory Scale (WMS). Part A of digit span (the forward span) captures attention efficiency and capacity, and part B (the backward span) is an executive task dependent on working memory. The Digit Span subtest will be scored as one summary value. The unit of measure is the total recall. Scores on this measure range from 0-48, where greater scores indicates greater attention efficiency, capacity and working memory.
Time frame: Change from Baseline to Week 8, 3 month follow up, 6 month follow up
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Digit Span | 8 weeks | 30.11 score on a scale | Standard Deviation 4.82 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Digit Span | 6 month follow-up | 31.13 score on a scale | Standard Deviation 4.38 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Digit Span | 3 month follow-up | 30.73 score on a scale | Standard Deviation 4.97 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Digit Span | Baseline | 28.49 score on a scale | Standard Deviation 4.06 |
| Waitlist Control Group | The Digit Span | 6 month follow-up | 28.38 score on a scale | Standard Deviation 5.72 |
| Waitlist Control Group | The Digit Span | 3 month follow-up | 28.17 score on a scale | Standard Deviation 6.14 |
| Waitlist Control Group | The Digit Span | 8 weeks | 27.97 score on a scale | Standard Deviation 5.15 |
| Waitlist Control Group | The Digit Span | Baseline | 28.44 score on a scale | Standard Deviation 5.03 |
The Hopkins Verbal Learning Test-Revised (HVLT-R)
The Hopkins Verbal Learning Test-Revised (HVLT-R) is a brief assessment of verbal learning and memory (immediate recall, delayed recall, delayed recognition). When scoring the HVLT-R, the three learning trials are combined to calculate a total recall score; the delayed recall trial creates the delayed recall score; the retention (%) score is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. These scores are then converted to an age-based T score (Mean=50, SD=10). Higher scores represent better verbal learning and memory.
Time frame: Change from Baseline to Week 8, 3 month follow up, 6 month follow up
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Hopkins Verbal Learning Test-Revised (HVLT-R) | Baseline | 49.84 t score | Standard Deviation 10.72 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Hopkins Verbal Learning Test-Revised (HVLT-R) | 8 weeks | 49.11 t score | Standard Deviation 11.63 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Hopkins Verbal Learning Test-Revised (HVLT-R) | 3 month follow-up | 54.25 t score | Standard Deviation 9.66 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Hopkins Verbal Learning Test-Revised (HVLT-R) | 6 month follow-up | 55.94 t score | Standard Deviation 10.67 |
| Waitlist Control Group | The Hopkins Verbal Learning Test-Revised (HVLT-R) | 6 month follow-up | 54.54 t score | Standard Deviation 10.94 |
| Waitlist Control Group | The Hopkins Verbal Learning Test-Revised (HVLT-R) | 3 month follow-up | 53.36 t score | Standard Deviation 11.47 |
| Waitlist Control Group | The Hopkins Verbal Learning Test-Revised (HVLT-R) | 8 weeks | 50.19 t score | Standard Deviation 10.95 |
| Waitlist Control Group | The Hopkins Verbal Learning Test-Revised (HVLT-R) | Baseline | 49.22 t score | Standard Deviation 12.64 |
The Insomnia Severity Index (ISI)
The ISI is designed to specifically assess the severity of insomnia symptoms, the impact on daytime functioning, and the amount of associated distress. The ISI has 7 questions, which are summed to compute a total score. The range of the ISI is 0-28 with the higher the value, the more severe the insomnia severity.
Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Insomnia Severity Index (ISI) | 4 weeks | 9.67 score on Insomnai Severity Index | Standard Deviation 4.01 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Insomnia Severity Index (ISI) | 3 months follow-up | 7.11 score on Insomnai Severity Index | Standard Deviation 4.84 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Insomnia Severity Index (ISI) | 8 weeks | 6.03 score on Insomnai Severity Index | Standard Deviation 3.9 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Insomnia Severity Index (ISI) | 6 months follow-up | 7.94 score on Insomnai Severity Index | Standard Deviation 5.6 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Insomnia Severity Index (ISI) | Basline | 17.27 score on Insomnai Severity Index | Standard Deviation 3.53 |
| Waitlist Control Group | The Insomnia Severity Index (ISI) | 6 months follow-up | 6.28 score on Insomnai Severity Index | Standard Deviation 4.23 |
| Waitlist Control Group | The Insomnia Severity Index (ISI) | Basline | 15.06 score on Insomnai Severity Index | Standard Deviation 4.57 |
| Waitlist Control Group | The Insomnia Severity Index (ISI) | 4 weeks | 9.77 score on Insomnai Severity Index | Standard Deviation 4.81 |
| Waitlist Control Group | The Insomnia Severity Index (ISI) | 8 weeks | 6.34 score on Insomnai Severity Index | Standard Deviation 4.3 |
| Waitlist Control Group | The Insomnia Severity Index (ISI) | 3 months follow-up | 6.37 score on Insomnai Severity Index | Standard Deviation 4.6 |
The Work Productivity and Activity Impairment (WPAI)
The WPAI questionnaire was developed for the purpose of collecting productivity loss data within clinical trials and is suitable for direct translation into a monetary figure. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Time frame: Change from Baseline to Week 8, 3 month follow up, 6 month follow up
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Work Productivity and Activity Impairment (WPAI) | Baseline | 23.33 percentage of work productivity loss | Standard Deviation 34.04 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Work Productivity and Activity Impairment (WPAI) | 8 weeks | 7.42 percentage of work productivity loss | Standard Deviation 21.48 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Work Productivity and Activity Impairment (WPAI) | 3 month follow-up | 6.25 percentage of work productivity loss | Standard Deviation 20.14 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | The Work Productivity and Activity Impairment (WPAI) | 6 month follow-up | 5.77 percentage of work productivity loss | Standard Deviation 19.36 |
| Waitlist Control Group | The Work Productivity and Activity Impairment (WPAI) | 6 month follow-up | 5.63 percentage of work productivity loss | Standard Deviation 19.92 |
| Waitlist Control Group | The Work Productivity and Activity Impairment (WPAI) | 8 weeks | 11.54 percentage of work productivity loss | Standard Deviation 28.05 |
| Waitlist Control Group | The Work Productivity and Activity Impairment (WPAI) | Baseline | 18.28 percentage of work productivity loss | Standard Deviation 31.29 |
| Waitlist Control Group | The Work Productivity and Activity Impairment (WPAI) | 3 month follow-up | 5.85 percentage of work productivity loss | Standard Deviation 20.37 |
Total Sleep Time Measured by The Consensus Sleep Diary (CSD):
The sleep diary will be used to calculate total sleep time. The score is reported in minutes and is averaged over the whole week for the total sleep time.
Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Total Sleep Time Measured by The Consensus Sleep Diary (CSD): | 4 weeks | 358.77 minutes | Standard Deviation 64.05 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Total Sleep Time Measured by The Consensus Sleep Diary (CSD): | 3 month follow-up | 412.06 minutes | Standard Deviation 68.69 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Total Sleep Time Measured by The Consensus Sleep Diary (CSD): | 8 weeks | 392.14 minutes | Standard Deviation 52.52 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Total Sleep Time Measured by The Consensus Sleep Diary (CSD): | 6 month follow-up | 401.42 minutes | Standard Deviation 84.67 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Total Sleep Time Measured by The Consensus Sleep Diary (CSD): | Baseline | 370.06 minutes | Standard Deviation 67.72 |
| Waitlist Control Group | Total Sleep Time Measured by The Consensus Sleep Diary (CSD): | 6 month follow-up | 429.24 minutes | Standard Deviation 56.6 |
| Waitlist Control Group | Total Sleep Time Measured by The Consensus Sleep Diary (CSD): | Baseline | 378.41 minutes | Standard Deviation 81.09 |
| Waitlist Control Group | Total Sleep Time Measured by The Consensus Sleep Diary (CSD): | 4 weeks | 376.08 minutes | Standard Deviation 59.71 |
| Waitlist Control Group | Total Sleep Time Measured by The Consensus Sleep Diary (CSD): | 8 weeks | 406.40 minutes | Standard Deviation 57.11 |
| Waitlist Control Group | Total Sleep Time Measured by The Consensus Sleep Diary (CSD): | 3 month follow-up | 418.81 minutes | Standard Deviation 62.12 |
Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)
The sleep diary will be used to calculate wake after sleep onset, which refers to periods of wakefulness occurring after defined sleep onset. The score is reported in minutes and is averaged over the whole week for the total wake after sleep onset.
Time frame: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up
Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD) | 4 weeks | 23.32 minutes | Standard Deviation 17.3 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD) | 3 month follow-up | 20.06 minutes | Standard Deviation 20.46 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD) | 8 weeks | 21.84 minutes | Standard Deviation 19.8 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD) | 6 month follow-up | 21.46 minutes | Standard Deviation 20.24 |
| Cognitive Behaviour Therapy for Insomnia (CBT-I) | Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD) | Baseline | 63.29 minutes | Standard Deviation 41.99 |
| Waitlist Control Group | Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD) | 6 month follow-up | 21.85 minutes | Standard Deviation 20.34 |
| Waitlist Control Group | Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD) | Baseline | 50.80 minutes | Standard Deviation 34.14 |
| Waitlist Control Group | Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD) | 4 weeks | 19.90 minutes | Standard Deviation 14.87 |
| Waitlist Control Group | Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD) | 8 weeks | 20.06 minutes | Standard Deviation 18.95 |
| Waitlist Control Group | Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD) | 3 month follow-up | 22.87 minutes | Standard Deviation 19.86 |